{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Renal+Allograft+Rejection&page=2",
    "query": {
      "condition": "Acute Renal Allograft Rejection",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Renal+Allograft+Rejection&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T11:57:59.805Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04046549",
      "title": "A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allografts",
        "Rejection; Transplant, Kidney",
        "Transplant Rejection",
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "VIB4920",
          "type": "DRUG"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-10-30",
      "completion_date": "2023-03-22",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04046549"
    },
    {
      "nct_id": "NCT02911714",
      "title": "Contrast-Enhanced Ultrasound for Kidney Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Lumason Contrast-Enhanced Ultrasound",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-02-21",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02911714"
    },
    {
      "nct_id": "NCT00235300",
      "title": "An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cadaveric Donor Renal Transplantation",
        "Acute Renal Allograft Rejection",
        "Induction Therapy"
      ],
      "interventions": [
        {
          "name": "Thymoglobulin [Anti-thymocyte Globulin (rabbit)]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Simulect (basliximab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2000-05",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2015-03-18",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235300"
    },
    {
      "nct_id": "NCT01666951",
      "title": "Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "LCP-Tacro tablets",
          "type": "DRUG"
        },
        {
          "name": "Prograf",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-11",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2015-07-07",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 13,
      "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666951"
    },
    {
      "nct_id": "NCT00697996",
      "title": "Rituximab for Pediatric Renal Transplant Rejection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Rituximab for transplant rejection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "5 Years to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2005-06",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2008-12-23",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00697996"
    },
    {
      "nct_id": "NCT06438107",
      "title": "Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Renal Transplant Rejection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-04",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06438107"
    },
    {
      "nct_id": "NCT00695097",
      "title": "The Effect of Rituximab on the Development of Anti-Donor Antibodies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "No Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2004-08",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-03-26",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • San Francisco, California",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00695097"
    },
    {
      "nct_id": "NCT05477082",
      "title": "Blood Biomarkers in Pediatric Kidney Transplant Recipients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rejection of Kidney Allograft"
      ],
      "interventions": [
        {
          "name": "Observational group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 27,
      "start_date": "2023-08-21",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05477082"
    },
    {
      "nct_id": "NCT00817206",
      "title": "Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "LCP-Tacro",
          "type": "DRUG"
        },
        {
          "name": "Prograf",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2008-12",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2015-09-10",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00817206"
    },
    {
      "nct_id": "NCT02102854",
      "title": "Single Dose rATG for Renal Allograft Rejection",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute (Cellular) Renal Allograft Rejection"
      ],
      "interventions": [
        {
          "name": "rATG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-03",
      "completion_date": "2021-10",
      "has_results": false,
      "last_update_posted_date": "2020-09-03",
      "last_synced_at": "2026-07-24T11:57:59.805Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02102854"
    }
  ]
}